Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation

NCT04271956 ↗

Phase 2 Recruiting 83 enrolled German CLL Study Group

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation

Timeline

Start: 2020-02-19
Primary completion: 2026-08
Completion: 2026-08

Publications

Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, Schetelig J, von Tresckow J, Vehling-Kaiser U, Gaska T, Wendtner CM, Chapuy B, Fischer K, Kreuzer KA, Stilgenbauer S, Staber P, Niemann C, Hallek M, Eichhorst B. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. Nat Med. 2024 Jan;30(1):240-248. doi: 10.1038/s41591-023-02722-9. Epub 2023 Dec 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sonrotoclax	Other / unclassified	320 mg	Oral
Subject	Tislelizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Zanubrutinib	Small molecule	160 mg	Oral

Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation

Summary

Timeline

Publications

Drugs

Indications